Archive

Archive(1)

Hot Papers(1,022)

Ago/siRNA/saRNA(153)
Alternative splicing(92)
Anti-miR/antagomir(118)
antisense(10)
Antisense/RNase H(186)
Aptamer(141)
ASO(1)
circRNA(23)
Clinical Development(68)
Covid-19(1)
Delivery(124)
Gene editing(87)
Immune Stimulation(30)
Immunostimulation(4)
immunostimulation(7)
Long noncoding RNA(95)
Medicinal Chemistry(67)
MicroRNA(178)
mRNA(58)
Other papers of interest(137)
Pre-Clinical Research(47)
Reviews(100)
Ribozyme(30)
siRNA(16)
Splice modulation(43)
Toxicology(31)

Paper of the Month(33)

The 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)

October 11–14, 2026 | Denver, CO

Stay Updated!

OTS Webinars

Events Calendar

Annual Meetings

The 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)

October 11–14, 2026 | Denver, CO

Stay Updated!

OTS Webinars

Events Calendar

Annual Meetings

Category

Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.

Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin-Mediated Amyloidosis.

Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment.

Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.

RNA Interference Therapy with ARC-520 Results in Prolonged HBsAg Response in Patients with Chronic Hepatitis B Infection.

Category

Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.

Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin-Mediated Amyloidosis.

Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment.

Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.

RNA Interference Therapy with ARC-520 Results in Prolonged HBsAg Response in Patients with Chronic Hepatitis B Infection.

Subscribe to our Newsletter

Resources

Stay Connected

Search

The 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)

October 11–14, 2026 | Denver, CO

Stay Updated!

OTS Webinars

Events Calendar

Annual Meetings

The 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)

October 11–14, 2026 | Denver, CO

Stay Updated!

OTS Webinars

Events Calendar

Annual Meetings

Category

Category

Subscribe to our Newsletter

Resources

Stay Connected

Search

Login to your account

Reset Password

Signup to your Account

Answers

Job Alerts

Account Activation